Atrial fibrillation is a clinically significant cardiac arrhythmia that increases the risk of stroke by 3 to 4 times. Oral anticoagulation has been shown to mitigate stroke risk by two-thirds among patients with AF and is widely recommended in optimizing AF management.Direct oral anticoagulants have also been demonstrated to be superior to warfarin with respect to the risk of fatal bleeding and stroke prevention. However, the previous study finding highlighted a great gap between current guidelines and the clinical management of AF .Nonetheless, the decision for anticoagulant use is not straightforward.It is worth to investigate the updated prevalence of anticoagulant use, the reasons for not receiving anticoagulant, and the factors independently associated with anticoagulant refusal in patients with non-valvular atrial fibrillation.
Study Type
OBSERVATIONAL
Enrollment
300
no intervention
LIAO, Jiawei
Hong Kong, Hong Kong
The prevalence of anticoagulant use in non-valvular atrial fibrillation patients
calculate the prevalence of anticoagulant use in non-valvular atrial fibrillation patients
Time frame: August 2019 to March 2020
the rate of the refusal of anticoagulant use
calculate the rate of refusal of anticoagulant use in the eligible non-valvular atrial fibrillation patients
Time frame: August 2019 to March 2020
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.